Acurx Pharmaceuticals Llc Stock EBITDA
| ACXP Stock | USD 1.35 0.05 3.85% |
Acurx Pharmaceuticals LLC fundamentals help investors to digest information that contributes to Acurx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acurx Stock. The fundamental analysis module provides a way to measure Acurx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acurx Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -14.6 M | -15.3 M |
Acurx | EBITDA |
Acurx Pharmaceuticals LLC Company EBITDA Analysis
Acurx Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Acurx Pharmaceuticals EBITDA | (14.58 M) |
Most of Acurx Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acurx Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Acurx EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Acurx Pharmaceuticals is extremely important. It helps to project a fair market value of Acurx Stock properly, considering its historical fundamentals such as EBITDA. Since Acurx Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acurx Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acurx Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Acurx Ebitda
According to the company disclosure, Acurx Pharmaceuticals LLC reported earnings before interest,tax, depreciation and amortization of (14.58 Million). This is 101.66% lower than that of the Biotechnology sector and 114.56% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.37% higher than that of the company.
Acurx EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acurx Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acurx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acurx Pharmaceuticals by comparing valuation metrics of similar companies.Acurx Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Acurx Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Acurx Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acurx Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acurx Pharmaceuticals' value.| Shares | Patriot Financial Group Insurance Agency, Llc | 2024-09-30 | 10.4 K | Tocqueville Asset Management L.p. | 2024-09-30 | 10 K | Semmax Financial Advisors Inc. | 2024-06-30 | 5.9 K | Group One Trading, Lp | 2024-06-30 | 5.2 K | Tower Research Capital Llc | 2024-06-30 | 4.1 K | Cornerstone Planning Group Llc | 2024-06-30 | 3.3 K | Simplex Trading, Llc | 2024-06-30 | 2.9 K | Northwestern Mutual Wealth Management Co | 2024-06-30 | 1.6 K | Ubs Group Ag | 2024-06-30 | 881 | Vanguard Group Inc | 2024-09-30 | 529.3 K | Prospect Financial Services Llc | 2024-09-30 | 295.1 K |
Acurx Fundamentals
| Return On Equity | -3.47 | ||||
| Return On Asset | -1.32 | ||||
| Current Valuation | 16.2 M | ||||
| Shares Outstanding | 16.89 M | ||||
| Shares Owned By Insiders | 14.80 % | ||||
| Shares Owned By Institutions | 11.96 % | ||||
| Number Of Shares Shorted | 474.48 K | ||||
| Price To Book | 8.24 X | ||||
| EBITDA | (14.58 M) | ||||
| Net Income | (14.58 M) | ||||
| Cash And Equivalents | 9.09 M | ||||
| Cash Per Share | 0.80 X | ||||
| Total Debt | 3.04 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 19.43 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (9.8 M) | ||||
| Short Ratio | 12.59 X | ||||
| Earnings Per Share | (1.09) X | ||||
| Target Price | 11.19 | ||||
| Beta | -1.72 | ||||
| Market Capitalization | 21.96 M | ||||
| Total Asset | 7.71 M | ||||
| Retained Earnings | (53.22 M) | ||||
| Working Capital | 4.67 M | ||||
| Net Asset | 7.71 M |
About Acurx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acurx Pharmaceuticals LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acurx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acurx Pharmaceuticals LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Acurx Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acurx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acurx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Acurx Stock
Moving against Acurx Stock
| 0.5 | RNXT | RenovoRx | PairCorr |
| 0.48 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.31 | KEP | Korea Electric Power | PairCorr |
The ability to find closely correlated positions to Acurx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acurx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acurx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acurx Pharmaceuticals LLC to buy it.
The correlation of Acurx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acurx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acurx Pharmaceuticals LLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acurx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.